NeOnc included in cancer breakthrough roundup
A GlobeNewswire press release highlights NeOnc Technologies among several 2026 cancer-development updates, including its Phase 2a NEO100 survival findings in recurrent high-grade brain cancer. The piece is a promotional roundup rather than a new market-moving company event.